Literature DB >> 2157389

Infectious bursal disease virus variant from commercial Leghorn pullets.

N M Ismail1, Y M Saif, W L Wigle, G B Havenstein, C Jackson.   

Abstract

An infectious bursal disease virus (IBDV) was isolated from 39-to-43-day-old commercial leghorn pullets suspected of having infectious bursal disease (IBD). These chickens had been vaccinated with a commercial live IBDV vaccine at 28 and 35 days of age. An isolate designated IN was recovered using specific-pathogen-free (SPF) chickens and the BGM-70 established cell line. Experimental studies using SPF chickens vaccinated with either inactivated vaccines made from the vaccine strain used in the problem flock or a standard-type vaccine indicated no protection against the IN isolate. However, two variants and another standard-type vaccine induced protection against the IN isolate. Cross-neutralization tests indicated that the IN isolate differed antigenically from commercial vaccine strains and was related to the variant IBDV strains recently isolated from broilers. To our knowledge, this is the first report of a variant IBDV recovered from commercial layer chickens in the United States.

Entities:  

Mesh:

Year:  1990        PMID: 2157389

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  10 in total

1.  Naturally occurring-neutralizing monoclonal antibody escape variants define the epidemiology of infectious bursal disease viruses in the United States.

Authors:  D B Snyder; V N Vakharia; P K Savage
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Molecular epizootiology of infectious bursal disease (IBD) in Korea.

Authors:  Woo-Jin Jeon; Kang-Seuk Choi; Dong-Woo Lee; Eun-Kyoung Lee; Sang-Ho Cha; Sun-Hee Cho; Jun-Hun Kwon; Yeo-sung Yoon; Sun-Joong Kim; Jae-Hong Kim; Hyuk-Joon Kwon
Journal:  Virus Genes       Date:  2009-09-01       Impact factor: 2.332

3.  Sequence conservation in the RNA polymerase gene of infectious bursal disease viruses.

Authors:  F S Kibenge; B Qian
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

4.  Determination of the 5' and 3' terminal noncoding sequences of the bi-segmented genome of the avibirnavirus infectious bursal disease virus.

Authors:  F S Kibenge; M M Nagarajan; B Qian
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

5.  Enzyme-linked immunosorbent assay-based detection of antibodies to antigenic subtypes of infectious bursal disease viruses of chickens.

Authors:  D J Jackwood; K S Henderson; R J Jackwood
Journal:  Clin Diagn Lab Immunol       Date:  1996-07

6.  Biological roles of the major capsid proteins and relationships between the two existing serotypes of infectious bursal disease virus.

Authors:  S K Reddy; A Silim; M J Ratcliffe
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

7.  Molecular and structural bases for the antigenicity of VP2 of infectious bursal disease virus.

Authors:  Tobias Letzel; Fasseli Coulibaly; Felix A Rey; Bernard Delmas; Erik Jagt; Adriaan A M W van Loon; Egbert Mundt
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

8.  Differential modulation of cytokine, chemokine and Toll like receptor expression in chickens infected with classical and variant infectious bursal disease virus.

Authors:  Abdul Rauf; Mahesh Khatri; Maria V Murgia; Kwonil Jung; Yehia M Saif
Journal:  Vet Res       Date:  2011-07-12       Impact factor: 3.683

9.  Characterization of variant infectious bursal disease virus from a broiler farm in Japan using immunized sentinel chickens.

Authors:  Kenichi Yamazaki; Hideyuki Ohta; Toru Kawai; Tsuyoshi Yamaguchi; Takeshi Obi; Kozo Takase
Journal:  J Vet Med Sci       Date:  2016-10-27       Impact factor: 1.267

10.  Evaluating the Breadth of Neutralizing Antibody Responses Elicited by Infectious Bursal Disease Virus Genogroup A1 Strains Using a Novel Chicken B-Cell Rescue System and Neutralization Assay.

Authors:  Vishwanatha R A P Reddy; Salik Nazki; Andrew J Brodrick; Amin Asfor; Joanna Urbaniec; Yasmin Morris; Andrew J Broadbent
Journal:  J Virol       Date:  2022-09-07       Impact factor: 6.549

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.